NeuroSense Therapeutics Ltd. (NRSN)
NASDAQ: NRSN · Real-Time Price · USD
0.5030
-0.0388 (-7.16%)
At close: Aug 6, 2026, 4:00 PM EDT
0.5000
-0.0030 (-0.60%)
Pre-market: Aug 7, 2026, 4:32 AM EDT
NeuroSense Therapeutics Employees
NeuroSense Therapeutics had 17 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
17
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$654,412
Market Cap
17.78M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 17 | 0 | - |
| Dec 31, 2024 | 17 | -1 | -5.56% |
| Dec 31, 2023 | 18 | 4 | 28.57% |
| Dec 31, 2022 | 14 | 3 | 27.27% |
| Dec 31, 2021 | 11 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| NextCure | 40 |
| Citius Pharmaceuticals | 23 |
| Jasper Therapeutics | 22 |
| Quantum BioPharma | 17 |
| Lipocine | 14 |
| Werewolf Therapeutics | 14 |
| NewcelX | 12 |
NRSN News
- 20 hours ago - NeuroSense sees December 2026 as filing date for NDS for PrimeC - TheFly
- 21 hours ago - NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada - PRNewsWire
- 8 days ago - NeuroSense Therapeutics Registration statement: Registration filing - Filings
- 10 days ago - NeuroSense Therapeutics Slides: Corporate presentation - Filings
- 15 days ago - NeuroSense to file NDS to Health Canada for PrimeC for treatment of ALS - TheFly
- 16 days ago - NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS - PRNewsWire
- 4 weeks ago - NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS" - PRNewsWire
- 5 weeks ago - NeuroSense says Phase 2b PARADIGM study of PrimeC in ALS met endpoint - TheFly